menu
    • menu
    [{"orgOrder":0,"company":"Neuronasal","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Acetylcysteine","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Neuronasal","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"intranasal","sponsorNew":"Neuronasal \/ ATAI Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Neuronasal \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Auditus","sponsor":"Oblato","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Acetylcysteine","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Auditus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"","sponsorNew":"Auditus \/ Oblato","highestDevelopmentStatusID":"8","companyTruncated":"Auditus \/ Oblato"},{"orgOrder":0,"company":"Neuronasal","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Acetylcysteine","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Neuronasal","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Neuronasal \/ ATAI","highestDevelopmentStatusID":"5","companyTruncated":"Neuronasal \/ ATAI"},{"orgOrder":0,"company":"Neuronasal","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Acetylcysteine","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Neuronasal","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"intranasal","sponsorNew":"Neuronasal \/ ATAI Life Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Neuronasal \/ ATAI Life Sciences"},{"orgOrder":0,"company":"ImmunoFlex","sponsor":"Chemistree","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Acetylcysteine","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"ImmunoFlex","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ImmunoFlex \/ Chemistree","highestDevelopmentStatusID":"12","companyTruncated":"ImmunoFlex \/ Chemistree"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthetase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ashvattha Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kelso Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Acetylcysteine","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Kelso Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet, Effervescent","sponsorNew":"Kelso Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kelso Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Bucillamine","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Revive Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Acetylcysteine

    Menu

    Acetylcysteine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Revive Therapeutics

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Revive Therapeutics

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bucillamine,Acetylcysteine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Revive Updates Bucillamine for Nerve Agent Exposure with Canada’s Defence Research

                            Details : Bucillamine is a potent antioxidant and anti-inflammatory, small molecule drug candidate. It is being evaluated for the treatment of nerve agent induced brain injury seizure.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 16, 2024

                            Lead Product(s) : Bucillamine,Acetylcysteine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kelso Pharma

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Kelso Pharma

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acetylcysteine

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kelso Pharma Announces First Product Launch

                            Details : Acepiro (acetylcysteine) a mucolytic agents which reduces bronchial secretion viscosity to facilitate expectoration for clearing the airways. It is indicated in adults for respiratory tract diseases treatment.

                            Brand Name : Acepiro

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 30, 2023

                            Lead Product(s) : Acetylcysteine

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ashvattha Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Ashvattha Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acetylcysteine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ashvattha Therapeutics Announces Publication of Data in Science Translational Medicine from Phase 2a Clinical ...

                            Details : Data showed OP-101 (N-acetyl Cysteine) delivered intravenously may have the potential to treat systemic inflammation and neuronal injury, reducing morbidity and mortality in hospitalized patients with severe COVID-19.

                            Brand Name : OP-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 25, 2022

                            Lead Product(s) : Acetylcysteine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ImmunoFlex

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ImmunoFlex

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acetylcysteine

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Chemistree

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chemistree Investee ImmunoFlex Receives Health Canada Approval For Flex 10 Product

                            Details : FLEX 10™ is ImmunoFlex's unique N-Acetyl-L-cysteine formulation in packs of 30 - 600 mg capsules. FLEX 10TM is a powerful antioxidant, specifically packaged in aluminum blisters to reduce the potential for product oxidation.

                            Brand Name : FLEX 10

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 19, 2021

                            Lead Product(s) : Acetylcysteine

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Chemistree

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Neuronasal

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Neuronasal

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acetylcysteine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : IND Enabling

                            Sponsor : ATAI Life Sciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Neuronasal, Inc. Announces Completion of Pilot Study, Receives IND Clearance to Continue into Phase I Trials o...

                            Details : Neuronasal has been granted Investigational New Drug (IND) clearance by the U.S. Food and Drug Administration (FDA) to continue its plans for a Phase I clinical trial, and is doing so in partnership with ATAI Life Sciences.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 12, 2020

                            Lead Product(s) : Acetylcysteine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : IND Enabling

                            Sponsor : ATAI Life Sciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Neuronasal

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Neuronasal

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acetylcysteine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : IND Enabling

                            Sponsor : ATAI Life Sciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ATAI Life Sciences Announces Neuronasal Completes Pilot Study, Receives IND Clearance to Continue into Phase I...

                            Details : Neuronasal's potentially ground-breaking proprietary treatment includes the intranasal delivery of low doses of N-acetylcysteine to patients with acute mild traumatic brain injury (mTBI). NAC has the potential to disrupt the deleterious chain of events f...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 21, 2020

                            Lead Product(s) : Acetylcysteine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : IND Enabling

                            Sponsor : ATAI Life Sciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Auditus

                            Country arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Auditus

                            Country arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acetylcysteine,2,4-disulfonyl alpha-phenyl tertiary butyl nitrone

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase II

                            Sponsor : Oblato

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Oblato Biotech Company Acquires Hearing Loss Drug

                            Details : Oblato assumes exclusive rights to a drug known as NHPN-1010. Oblato is expected to initiate a phase 2 clinical trial to evaluate the potential of the drug to prevent and treat hearing loss.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 12, 2020

                            Lead Product(s) : Acetylcysteine,2,4-disulfonyl alpha-phenyl tertiary butyl nitrone

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase II

                            Sponsor : Oblato

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Neuronasal

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Neuronasal

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acetylcysteine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Undisclosed

                            Sponsor : ATAI Life Sciences

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            ATAI Life Sciences Partners with Neuronasal Inc. to Develop Novel Treatment for mild Traumatic Brain Injury (m...

                            Details : The partners will develop a short-term treatment which includes intranasal delivery of low doses of N-acetylcysteine for mild Traumatic Brain Injury (mTBI) or concussion.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 06, 2020

                            Lead Product(s) : Acetylcysteine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Undisclosed

                            Sponsor : ATAI Life Sciences

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth